Clinical trial
LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active…
NCT00466258 · PETHEMA Foundation, Other · Completed
Key facts
| NCT number | NCT00466258 |
|---|---|
| Title | LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) |
| Official title | LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) |
| Acronym | LINFOTARGAM |
| Lead sponsor | PETHEMA Foundation, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections, Diffuse Large B Cell Lymphoma |
| Intervention type | Drug |
| Interventions | R-CHOP, Highly active antiretroviral therapy, Central nervous system (CNS) prophylaxis, Prophylaxis of opportunistic infections and support treatment |
| Enrollment | 50 |
| Start date | Oct 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Apr 27, 2007 |
| Last update posted | Nov 25, 2009 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: